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Objectives: In COPD, disturbed sleep is related to exacerbation frequency, poor 
quality of life and early mortality. We developed the Manchester Sleep Symptoms 
Index (MSSI) to assess night-time symptoms and disturbed sleep in COPD. MethOds: 
Identification of potential items was guided by interviews and focus groups involving 
COPD patients and age-matched controls. Hierarchical methods and Rasch analysis 
informed item deletion and development of a unidimensional scale. Internal con-
sistency and test-retest reliability were assessed. Concurrent validity was examined 
using Pearson’s correlation with the St George’s Respiratory Questionnaire (SGRQ), 
modified MRC Dyspnoea Scale, FACIT fatigue scale, MOS Sleep Scale, HADS Anxiety 
and Depression scores. Results: Qualitative data from 36 patients with COPD and 
10 age-matched controls informed an initial list of 22 items. The cross-sectional study 
included 203 COPD patients (GOLD: I: 14% II: 41% III: 25% IV: 7%; male: 63%, mean 
age: 64.7; SD: 7.5 years) and 50 non-COPD controls. 12 items were removed during 
hierarchical methods and a further two following Rasch analysis. The final MSSI 
contains 8 sleep-related items that are specific to COPD patients: breathlessness, 
chest tightness, cough and sputum production. The index has good internal consist-
ency (Cronbach’s alpha 0.87), test-retest repeatability (intra-class coefficient 0.77) 
and validity. Total MSSI scores significantly correlated with the SGRQ (r= 0.64); MRC 
Dyspnoea scale (r= 0.46), FACIT-F (r= -0.61); MOS problems index 2: (r= 0.62); MOS Sleep 
adequacy (r= 0.40); MOS Sleep disturbance (r= 0.53) HADS anxiety (r= 0.54) and depres-
sion (0.48). There was good overall fit to the Rasch model (Chi-squared: 29.2 df: 16 
p= 003.) and distribution of item scores. cOnclusiOns: The MSSI is a reliable, valid, 
uni-dimensional self-reported outcome measure of sleep and night-time symptoms 
for people with COPD. It is simple and quick to use making it suitable for research 
and practice. Further work is needed to determine the minimal clinical important 
difference and cross cultural validity.
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Objectives: The objective of this study was to evaluate the psychometric properties 
of a new patient-reported measure of knee implant functional performance associ-
ated with physical activities prior to and following primary total knee arthroplasty 
(TKA). The Patient’s Knee Implant Performance questionnaire (PKIP) was developed 
to assess factors that lead to patient dissatisfaction and describe unmet needs 
in knee functional performance. MethOds: The psychometric analysis sample 
(n= 764) was based on a multicenter, prospective, noncomparative longitudinal study 
of patients with osteoarthritis undergoing TKA at 22 international sites. The PKIP 
and additional patient-reported outcomes and clinical measures were collected 
preoperatively, postoperatively at less than 1 year, at a minimum of 1 year, and at 2 
years. The PKIP structure and its reliability, construct validity, discriminating abil-
ity, and responsiveness were assessed. Results: Based on inter-item correlations, 
factor analyses, and results of previous qualitative research, the PKIP was scored as 
four subscales (Stability, Confidence, Satisfaction, and Activity Modification) and 
an Overall PKIP score. The Overall PKIP score met reliability standards (internal 
consistency: alpha = 0.78 at minimum 1 year; test-retest: intraclass correlation coef-
ficient = 0.77). Correlations between the PKIP and other available measures provided 
evidence of construct validity. For example, the PKIP correlated 0.19 and 0.50 with 
the American Knee Society Score preoperatively and at less than 1 year, respectively, 
and correlated 0.69 and 0.77, with the Knee Injury and Osteoarthritis Outcome Score 
Quality of Life subscale. The PKIP was capable of discriminating between groups 
of patients with better or worse knee functioning as defined by clinician-rated 
measures; hypothesis tests were in the predicted direction and mostly statistically 
significant. The effect size for the Overall PKIP score was 2.38, indicating that the 
PKIP was highly responsive. cOnclusiOns: The reliability, validity, and responsive-
ness of the PKIP support its use among patients undergoing primary TKA.
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Objectives: To evaluate the validity of the BRAF-MDQ in a new group of patients 
in a clinical trial setting, to confirm its internal factor (domain) structure and to 
document its sensitivity to change. MethOds: Pooled data from a randomized 
controlled trial (NCT01242488) in patients with moderate to severe RA were col-
lected at baseline (BL), Wk10 and Wk12. Spearman’s correlation coefficients, 
Bland-Altman plots and confirmatory factor analysis tested construct validity, 
reproducibility and internal factor structure of the BRAF-MDQ. Responsiveness 
was assessed amongst clinical responders at Wk12 by effect sizes of changes from 
BL in BRAF-MDQ. Results: There were 219 patients (mean age: 55.5 years; disease 
duration: 12.6 years; BL DAS28: 5.77). The proportion of missing item answers was 
very low (0–3%). BRAF-MDQ scores correlated with patient global, pain and HAQ at 
BL (r= 0.49, 0.46 and 0.58) and at Wk12 (r= 0.63, 0.65 and 0.64). Changes in the Physical 
and Living domains were more closely related to changes in patient and physician 
global scores and DAS scores than did changes in Cognition and Emotional domains. 
Reproducibility was high (r> 0.87 for all total and domain scores; narrow Bland-
Altman limits of agreement), as was internal consistency (Cronbach’sa: 0.97 for total 
scores; > 0.82 for each domain at BL). The Butler comparative fit index (CFI; 0.92) 
indicated that the established structure within the BRAF-MDQ accounts well for data 
variation. Effect sizes for BRAF-MDQ in clinical responders at Wk12 were very high 
Objectives: To explore how participants evaluate and complete the choice tasks 
in Discrete Choice Experiments (DCE), with special attention to the impact of edu-
cational level and health literacy. MethOds: Two existing DCE questionnaires on 
rotavirus vaccination and prostate cancer screening served as a case for the current 
study. In total, 70 participants were sampled based on educational level (35 per case 
study). During structured interviews, participants completed five choice tasks aloud. 
Interviewers monitored how participants read the choice tasks, how they interpreted 
the included risk attributes and what decision strategy they used to make their deci-
sion and if the monotonicity and continuity axioms hold. Results: The majority of 
the participants read all the attributes within each choice task. Nearly all participants 
chose the scenario with the optimal attribute levels (monotonicity axiom). In accord-
ance with the continuity axiom, most participants mentioned three or more attributes 
when motivating their decisions. Overall, higher educated and literate participants 
more often included three or more attributes when motivating their decision and used 
trading between attributes more often as a decision strategy. cOnclusiOns: The 
majority of the participants complete a DCE as presumed by its underlying methodol-
ogy. However, the assumptions did not hold for a subset of lower educated and less 
literate participants. Based on participants’ age, educational level and health literacy 
additional measures should be undertaken to enhance participants’ understanding 
of the attributes, the attribute levels and the choice tasks in a DCE.
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Objectives: To assess the feasibility of a computer-based Standard Gamble (SG) 
visual prop whilst measuring utilities of different asthma health states at the same 
time. MethOds: Twenty adult asthma patients literate in either Malay or English 
language were conveniently sampled from a public hospital in Penang, Malaysia. 
They were interviewed by two trained interviewers using a bilingual script. Each 
patient was requested to value the given health states using Visual Analogue Scale 
(VAS) prior to SG exercise. There were three chronic health states (C1-C3) for 10 years, 
three temporary states (T1-T3) for 3 months, and two anchor states (healthy and 
dead). During the SG exercise, the visual prop was fully operated by the interviewers. 
The probability of being in a worse state was changed in a ‘ping-pong’ fashion until 
the indifference point was reached. Results: All patients understood the SG exer-
cise and rated SG easier than VAS. Around 85% (n= 17) completed SG within 30 min-
utes. There was 90% (n= 18) who ranked T3 as the worst temporary health state during 
VAS. Two patients provided logical inconsistency data in SG. The preferences by SG 
were higher than VAS. Preferences were also higher in temporary states measured 
by chained SG than other states by conventional SG. The mean utilities for C1= 0.56 
(SD 0.38), C2= 0.47 (SD 0.33), C3= 0.53 (SD 0.38), T1= 0.65 (SD 0.31), T2= 0.53 (SD 0.35), 
and T3= 0.38 (SD 0.38). cOnclusiOns: The SG methods including the props are 
feasible for utilities measurement in asthma, based on the agreements achieved 
with other studies on the pattern of utilities measured in this preliminary study.
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Objectives: Eliciting preferences has become increasingly important in health 
care. Several methods are available to evaluate the relative importance of different 
aspects of health and health care. In this study, we aim to examine the difference 
between a discrete-choice experiment (DCE) and a rating scale exercise (RSE) to 
determine the most important attributes of undergraduate students when select-
ing a study specialization. MethOds: First-year health sciences students were 
asked to complete a questionnaire that included a DCE and a RSE. Six attributes 
were identified in focus groups: “possible acquainted masters”, “job opportunity”, 
“scope of specialization”, “quality of education”, “hours self-study” and “personal 
interest”. Fourteen unlabeled choice tasks were constructed using a statistically 
efficient design and a mixed multinomial logistic regression analysis was used for 
data analysis. In the RSE, attributes were rated on perceived importance using a 
7-point Likert scale. Two versions of the questionnaire were distributed in which the 
RSE was put before and after the DCE. Results: A total of 254 students filled out 
the questionnaire. In the DCE, three attributes were statistically significant of which 
“personal interest” was the most important attribute followed by “job opportunity” 
and “quality of education”. In the RSE, all attributes except “hours of self-study” were 
rated 4 or higher. The RSE scores of the attributes with a relatively low importance in 
the DCE were significantly lower in the questionnaire version that started with DCE 
than in the other version. Results of the DCE did not significantly differ between the 
two questionnaire versions. cOnclusiOns: The DCE had a differentiating effect 
on the relative importance of attributes whereas in the RSE attributes were rated 
more equally and were, except for one, all considered important. Forcing respond-
ents to make first trade-offs between attributes (using a DCE) leads to lower RSE 
scores for less important attributes afterwards.
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chemotherapy treatment decision-making. MethOds: We embedded the validated 
Decisional Conflict Scale (DCS) into our discrete choice experiment survey exam-
ining preferences for chemotherapy treatment in early BrCa. Of the 1004 general 
population participants, 200 completed the DCS before (DCS-1; no GEP test score 
in scenario) and after (DCS-2; GEP test score added to scenario) the discrete choice 
experiment. The 16-item DCS was scored from 0-100 with five subscores. Mean 
total and subscores, standard deviations and change in scores were calculated, with 
significance based on matched pairs t-tests (p< 0.05). We anticipated GEP would 
decrease decisional conflict in individuals unsure of their chemotherapy treat-
ment decision. Results: As anticipated, total score and all subscores (uncertainty, 
informed, values clarity, support, and effective decision) decreased significantly (all 
p< 0.05) in the group of respondents (n= 33) who indicated uncertainty about tak-
ing chemotherapy in DCS-1 but changed to no chemotherapy after receiving a GEP 
test score in DCS-2. In the group of respondents (n= 25) who indicated they would 
undergo chemotherapy in DCS-1 but changed to unsure in DCS-2, their effective 
decision subscore increase significantly (24.5 to 34.5, p< 0.05). In the overall sample 
(n= 200), total decisional conflict decreased from DCS-1 to DCS-2 by 0.5 (p= 0.3) and 
all subscores had non-significant decreases with the exception of effective deci-
sion, which had a non-significant increase. cOnclusiOns: GEP influences chemo-
therapy treatment decisional conflict in individuals who are initially unsure in their 
treatment decision-making. However, we do not observe this effect in individuals 
who do not change their chemotherapy treatment decisions.
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Objectives: In oncology, the impact of interventions on health-related quality of life 
(HRQL) is traditionally modelled based on disease progression status. The aim of this 
analysis was to assess if more meaningful patterns exist in HRQL data, based on other 
clinically important events that should be considered in modelling utility. MethOds: 
HRQL data from the CA184-024 trial of ipilimumab plus dacarbazine in previously 
untreated patients with unresectable malignant melanoma were analysed. European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 
Core-30 (EORTC QLQ-C30) responses were mapped to a generic, preference-based 
measure (EORTC-8D) by means of a published and validated mapping algorithm. 
The utility observations available for each patient were used to examine the relation-
ships between HRQL and a number of disease- and time-based variables, including 
treatment effect, progression status and time to death, via a mixed effects regression 
model. Results: Progression status was found not to be significantly predictive of 
utility (p= 0.29). Of the variables considered, the strongest relationship was with time 
to death, the mixed effects model for which was significantly predictive of utility 
(p≤ 0.001). HRQL dropped as patients approached death; patients treated with ipili-
mumab had a utility of 0.86 if time to death was more than 1 year, which reduced to 
0.61 during the final month of life. The ipilimumab treatment variable was associated 
with a small negative coefficient (-0.02), accounting for the adverse event profile of the 
drug when added to dacarbazine (p= 0.06). cOnclusiOns: Analysis of the CA184-024 
HRQL data showed that time to death rather than progression status was significantly 
predictive of utility. Hence, modellers should carefully examine primary data to deter-
mine if a time to event approach or a progression based approach is appropriate to 
model utility best reflecting the pathology of the disease.
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Objectives: Rasch modelling theory and its extensions have become popular tools 
in assessing psychometric properties of patient-reportedoutcome (PRO) instru-
ments. Since the Rasch model assumes a unidimensional structure, it is important 
to assert that this assumption has not been violated. However, there has been much 
debate about using factor analysis as the first step to assess dimensionality or using 
the Rasch model directly to identify items not fitting the unidimensional model. 
This study uses simulated data to compare the two techniques to examine the uni-
dimensional assumptions.  MethOds: Simulated data that represent a typical PRO 
instrument are generated based on the following variables: sample size (200 or 400), 
number of factors (1,2, or 3), and correlation among factors (0.4 or 0.7). Each simu-
lated PRO assessment contains 15 items with 5 response categories. Exploratory 
factor analysis is conducted, and the number of factors proposed by the results 
are noted. A Rasch model theory analysis is also conducted, and the number of 
mis-fit items is noted. The unidimensional test associated with Rasch model is also 
conducted. Results: Preliminary results suggest that when there is one dominant 
factor, the Rasch results identify the simulated factor and it becomes the underlying 
trait. Items not belonging to the dominant factor are flagged as mis-fit items or as 
forming secondary factors based on the unidimensional test. In situations where 
there is no dominant factor, factor analysis is able to identify separate factors, 
whereas the results are inconsistent using Rasch model. cOnclusiOns: Rasch first 
or factor first? The preliminary findings suggest that, when there is prior knowledge 
of a dominant factor, Rasch modelling can be conducted first and will result in a 
unidimensional measure. When there is no prior knowledge of a dominant fac-
tor, then factor analysis should be conducted first to examine the dimensionality.
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(> 0.7) for the Physical domain, high (> 0.5) for the Total score and the Living domain 
and moderate (> 0.3) for the Cognition and Emotional domains. cOnclusiOns: The 
BRAF-MDQ was completed well by participants, related to appropriate measures 
of disease severity, retained its factor structure, gave reproducible results and was 
responsive to clinical change, confirming its validity as a measure of RA fatigue.
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Objectives: Patient-reported outcome (PRO) measures provide relevant information 
on how patients function and feel about their health. Such data are useful in clinical 
practice and registrational trials. Despite the importance of symptom assessment in 
CDAD, there is no validated PRO for Clostridium difficile-associated diarrhoea (CDAD). 
A qualitative research study was conducted to develop a CDAD PRO according to US 
FDA PRO guidelines. MethOds: Content development comprised 2 study phases, 
with input from an advisory group of 6 CDAD experts in Europe and North America. 
Phase I elicited patients’ experiences of CDAD symptoms in open-ended discussions 
during telephone interviews. Supplementary interviews obtained nurses’ observa-
tions. A draft PRO was developed following demonstration of concept saturation. 
Readability and translatability were assessed. Phase II involved 2 rounds of patient 
interviews, with revision of the draft PRO after each round. All patients were ≥ 18 
years old, with confirmed CDAD. IRB approval and participant informed consent 
were obtained. Results: Phase I interviews included 18 patients and 6 nurses in 
the United States; 16 additional patients were interviewed in Phase II. Patients were 
representative of the general CDAD population, and diverse in age, gender, and disease 
severity. Concept saturation was reached in Phase I for spontaneously reported CDAD 
symptoms. Items were organised in a draft conceptual framework with 5 hypoth-
esised domains: diarrhoea, abdominal discomfort, tiredness, lightheadedness, and 
other symptoms. Phase II demonstrated initial content validity of the 13-item draft 
daily diary (CDAD-DaySyms™). Participants reported the questions were clear, rel-
evant, and comprehensive; were able to use the instructions to complete the diary 
correctly; and considered the 24-hour recall period appropriate. cOnclusiOns: 
The CDAD-DaySyms™ captures symptoms relevant to CDAD patients, demonstrat-
ing initial content validity. To allow its use in clinical practice and CDAD clinical 
studies, final content and psychometric validity are being evaluated in 2 ongoing 
international clinical trials.
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Objectives: In phase II studies, alirocumab, a PCSK9 inhibitor administered via sub-
cutaneous injection, demonstrated significant reduction in LDL-C levels. The objective 
of this study was to conduct qualitative research to explore the concept of treatment 
acceptance in patients receiving a subcutaneous injection to support the develop-
ment and testing of a patient-reported outcome measure, the Injection-Treatment 
Acceptance Questionnaire (I-TAQ). MethOds: A literature review led to the targeting 
of ‘treatment acceptance’ as the measurement concept in preference to treatment 
satisfaction. Concepts generated from the literature and instrument review informed 
the drafting of 17 items in the I-TAQ; item wording was adapted from three validated 
instruments. Qualitative interviews were conducted among 29 US-English speaking 
patients participating in alirocumab’s phase III program who self-administered the 
treatment via autoinjector (n= 19) or pre-filled syringe (n= 10). First, concept elicitation 
(CE) questioning was used to elicit concepts relating to patients’ treatment experi-
ences and acceptance. The I-TAQ was then cognitively debriefed using “think-aloud” 
methods. Verbatim transcripts were analyzed using thematic analysis and Atlas. ti. 
Revisions were considered after each round of interviews. Results: Qualitative 
analysis of CE data indicated treatment acceptance to be high, with the following 
concepts identified as relevant: perceived efficacy, side effects, self-efficacy, conveni-
ence and overall acceptance. Ten (34%) patients reported an initial fear of needles, 
which subsided with no impact on discontinuation. Pain was not considered rel-
evant by patients, suggesting no pain associated with the injection. Five items were 
added following round 1 interviews, three were retained after round 2 testing and two 
were added at finalization, forming the conceptually comprehensive 22-item I-TAQ. 
Patients demonstrated good understanding of item wording, instructions, response 
scales and recall period. cOnclusiOns: Successive rounds of interviews resulted in a 
treatment acceptance measure with strong content validity. Next steps are to psycho-
metrically validate the I-TAQ in a population with experience of taking alirocumab.
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Objectives: Individuals with BrCa have high decisional conflict with respect to 
treatment decisions. GEP of tumours informs risk prediction, potentially affecting 
decisions about adjuvant chemotherapy in early BrCa, where only 15% will experi-
ence recurrence. We aimed to examine whether GEP reduces decisional conflict in 
